New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 5, 2014
04:55 EDTEBIO, EBIO, EBIO, EBIO, SURG, SURG, SURG, SURG, DNA, DNA, DNA, DNA, XOMA, XOMA, XOMA, XOMA, SQNM, SQNM, SQNM, SQNM, REGN, REGN, REGN, REGN, MRK, MRK, MRK, MRK, CAJ, CAJ, CAJ, CAJ, AGN, AGN, AGN, AGN, AGTC, AGTC, AGTC, AGTC, VRX, VRX, VRX, VRXAssociation for Research in Vision & Ophthalmology holds annual meeting
2014 Annual Meeting of ARVO is being held in Orlando, Florida on May 4-8.
News For EBIO;AGTC;AGN;CAJ;MRK;REGN;SQNM;XOMA;DNA;SURG;VRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
October 8, 2014
09:34 EDTCAJCanon downgraded to Equal Weight from Overweight at Morgan Stanley
Subscribe for More Information
08:42 EDTAGNSalix shares should be bought on weakness, says Sterne Agee
After Reuters yesterday afternoon reported that Actavis (ACT) plans to make a new merger approach to Allergan (AGN), Sterne Agee believes that Salix's standalone value is $162. The firm expects the shares to reach that level following approval of its Xifaxan IBS-D drug after the February 2015 PDUFA date.
07:19 EDTDNA, AGNCBI to hold a conference
Subscribe for More Information
07:18 EDTMRKInfectious Diseases Society of America to hold a conference
ID Week 2014 is being held in Philadelphia on October 8-12.
06:23 EDTVRX, AGNActavis more inclined to pursue Allergan over Salix, says Citigroup
Subscribe for More Information
October 7, 2014
18:29 EDTAGN, VRXOn The Fly: After Hours Movers
Subscribe for More Information
18:05 EDTVRX, AGNValeant, Pershing Square plan to raise Allergan bid by $15 a share, WSJ says
Subscribe for More Information
17:52 EDTVRX, AGNAllergan up 2.8% after Dow Jones says Valeant planning to boost bid for company
17:49 EDTAGN, VRXValeant up 3.9% after Dow Jones says planning to boost Allergan bid
Subscribe for More Information
17:47 EDTVRX, AGNValeant, Pershing Square planning to boost Allergan bid by $15 a share, DJ says
Subscribe for More Information
16:13 EDTAGTCPoint72 Asset reports 5.8% passive stake in Applied Genetic
Subscribe for More Information
15:21 EDTVRX, AGNAllergan warms to sale as Actavis plans new approach, Reuters says
Subscribe for More Information
15:01 EDTAGNAllergan up 1.5% following report on Actavis planned approach on merger
14:59 EDTAGNActavis plans new approach to Allergan, Reuters reports
Subscribe for More Information
10:18 EDTSQNMHigh option volume stocks
Subscribe for More Information
09:24 EDTSQNMMaxim recommends buying Sequenom
Subscribe for More Information
09:01 EDTSQNMSequenom acquisition a strategic positive, says Maxim
Subscribe for More Information
08:35 EDTEBIOEleven Biotherapeutics granted U.S. composition of matter patent for EBI-005
Eleven Biotherapeutics announced the issuance of U.S. Patent No. 8,853,150 entitled "Chimeric Il-1 Receptor Type I Agonists and Antagonists." This patent covers the composition-of-matter of Eleven’s lead product candidate, EBI-005, a topically-administered interleukin-1 receptor blocker, certain other compositions that are IL-1 receptor antagonists, and related methods for treating ocular surface inflammatory diseases, such as dry eye disease and allergic conjunctivitis. Designed, engineered and generated using Eleven’s AMP-Rx platform, EBI-005 is being developed as a topical protein therapeutic for ocular diseases. Eleven recently reported top-line results of a Phase 2 study of EBI-005 in patients with moderate to severe allergic conjunctivitis and is currently evaluating EBI-005 in a pivotal Phase 3 clinical study in patients with dry eye disease, with top-line data expected in early 2015. “This patent, which will expire in 2031, contains both composition-of-matter and methods of use claims and strengthens our intellectual property portfolio for EBI-005,” said Abbie Celniker, Ph.D., President and CEO. “We were pleased with the recently announced results of our Phase 2 clinical study of EBI-005 in patients with allergic conjunctivitis and look forward to reporting top-line, pivotal Phase 3 data in dry eye disease in early 2015.”
07:48 EDTAGNSalix reinstated with a Buy at Jefferies
Subscribe for More Information
07:12 EDTAGN, VRXAllergan requests Ackman be hindered from voting at meeting, Bloomberg says
In an effort to avoid an unsolicited $54B acquisition offer from Valeant Pharmaceuticals (VRX), Allergan (AGN) filed a request in a California court for a judge to hinder Bill Ackman’s Pershing Square from voting its 10% stake at the December shareholder meeting, according to Bloomberg, citing the filing. A hearing regarding Allergan's request is set to occur on October 28. Reference Link
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use